Covid-19
Atea secures Fast Track designation for Covid-19 drug bemnifosbuvir
Despite past challenges, the oral drug is now being studied in a global Phase III outpatient trial in Covid-19 that enrolled the first patient in November 2022.
Despite past challenges, the oral drug is now being studied in a global Phase III outpatient trial in Covid-19 that enrolled the first patient in November 2022.